CA2105378A1 - Compositions et methodes de traitement d'un certain nombre de troubles avec de l'etianate et des agonistes de l'etianate - Google Patents

Compositions et methodes de traitement d'un certain nombre de troubles avec de l'etianate et des agonistes de l'etianate

Info

Publication number
CA2105378A1
CA2105378A1 CA002105378A CA2105378A CA2105378A1 CA 2105378 A1 CA2105378 A1 CA 2105378A1 CA 002105378 A CA002105378 A CA 002105378A CA 2105378 A CA2105378 A CA 2105378A CA 2105378 A1 CA2105378 A1 CA 2105378A1
Authority
CA
Canada
Prior art keywords
etianate
administering
side effects
administration
toxic side
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002105378A
Other languages
English (en)
Inventor
Paolo A. Paciucci
James F. Holland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2105378A1 publication Critical patent/CA2105378A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
CA002105378A 1991-03-21 1992-03-20 Compositions et methodes de traitement d'un certain nombre de troubles avec de l'etianate et des agonistes de l'etianate Abandoned CA2105378A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67302691A 1991-03-21 1991-03-21
US07/673,026 1991-03-21
US71799591A 1991-06-20 1991-06-20
US07/717,995 1991-06-20

Publications (1)

Publication Number Publication Date
CA2105378A1 true CA2105378A1 (fr) 1992-09-22

Family

ID=27100871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002105378A Abandoned CA2105378A1 (fr) 1991-03-21 1992-03-20 Compositions et methodes de traitement d'un certain nombre de troubles avec de l'etianate et des agonistes de l'etianate

Country Status (4)

Country Link
EP (1) EP0581803A4 (fr)
JP (1) JPH06505491A (fr)
CA (1) CA2105378A1 (fr)
WO (1) WO1992016235A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303636B1 (fr) * 2015-06-03 2021-11-10 Aelan Cell Technologies, Inc. Méthodes d'accompagnement pour thérapies à base d'il-2 et thérapies à base de cellules souches mésenchymateuses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) * 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids

Also Published As

Publication number Publication date
EP0581803A1 (fr) 1994-02-09
JPH06505491A (ja) 1994-06-23
WO1992016235A1 (fr) 1992-10-01
EP0581803A4 (fr) 1994-03-18

Similar Documents

Publication Publication Date Title
Ettinghausen et al. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
US5932208A (en) Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
Brittenden et al. Natural killer cells and cancer
US5756085A (en) Use of interleukin-12 to prevent graft versus host disease
AU640954B2 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or H2-receptor agonists
US6165979A (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
EP0652768A1 (fr) Preparation pour l'activation de cellules tueuses naturelles, renfermant un interferon-alpha et une histamine, une serotonine ou des substances ayant une activite receptrice correspondante
Minasian et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma
AU707019B2 (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
HU215389B (hu) Eljárás hatóanyagként IL-4-et tartalmazó tömött tumorok kezelésére alkalmas gyógyszerkészítmények előállítására
Ortaldo et al. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice
van HAELST-PISANI et al. Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells
CA2105378A1 (fr) Compositions et methodes de traitement d'un certain nombre de troubles avec de l'etianate et des agonistes de l'etianate
McVicar et al. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro
US5871725A (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
Gambacorti-Passerini et al. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation
Li et al. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation
EP0561927B1 (fr) Compositions pharmaceutiques destinees au traitement des affections malignes a lymphocytes b
Thompson et al. The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity
Thomas et al. New therapeutic modalities for cancer
Herberman Therapy of cancer with interleukin-2-activated natural killer cells
Couldwell et al. Im m unology and Im m unotherapy of Intrinsic G lial Tum ors
Galvani et al. Endolymphatic delivery of IL2 in patients with melanoma and lymphoma
Marumo et al. Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application
Shau et al. Regulation of NK Cytotoxicity In Vivo in Patients Receiving IL-2

Legal Events

Date Code Title Description
FZDE Dead